重组人表皮生长因子对大鼠皮肤烧伤愈合的促进作用

目的:观察局部应用重组人表皮生长因子(recombined human epidermal growth factor,rhEGF)对大鼠皮肤深Ⅱ度烧伤有无促进作用.方法:建立约10%的大鼠烧伤面积,测定给不同剂量的rhEGF治疗后不同时间的烫伤创面愈合面积,创面组织病理组织学以及测定愈合时间来观察rhEGF对皮肤创伤的治疗作用.结果: rhEGF小、中、大剂量(每cm2创面200 IU,400 IU,800 IU)可以缩短大鼠皮肤深Ⅱ度烧伤愈合的时间,同一时间内烧伤愈合面积高于对照组,同时还可以增加表皮细胞和毛细血管的增生,三个剂量之间未见明显的量效反应.结论:局部应用rhEGF可以促进大鼠皮肤烧伤愈合.     

重组表皮生长因子对大鼠皮肤深Ⅱ度烫伤的治疗作用

目的：观察重组表皮生长因子对大鼠皮肤深Ⅱ度烫伤愈合有无促进作用。方法：采用大鼠深Ⅱ度烫伤模型,观察表皮生长因子(EGF)大、中、小剂量对烫伤创面的愈合作用。在建立约10％的烫伤面积后．每日一次给创面滴抹不同剂量的表皮生长因子(EGF)予以治疗,共用药7天。测定治疗后不同时间的创面愈合面积．并于治疗第7天取部分动物创面组织进行病理组织学检查。     

表皮生长因子联合血糖控制对糖尿病创面愈合的影响:成纤维细胞生长因子蛋白及其mRNA表达的变化

背景:有研究表明急性创伤可导致内源性的重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)表达下调,导致不愈合的发生。目的:观察局部应用rhEGF联合血糖控制下对糖尿病大鼠烫伤创面成纤维细胞生长因子表达的影响。方法:将Wistar糖尿病大鼠制备背部深Ⅱ度烫伤模型。联合治疗组于烫伤前1周控制血糖至对照组水平,并在烫伤24h内创面喷洒rhEGF;rhEGF组仅创面喷洒rhEGF;血糖控制组仅控制血糖;对照组不制备糖尿病模型,烫伤后处理同联合治疗组。烫伤后1,3,5,7,11,15,21d取创面皮肤组织采用免疫组织化学染色及原位杂交法检测成纤维细胞生长因子蛋白及mRNA的表达,并观察各组大鼠创面愈合情况。结果与结论:烫伤后各组大鼠创面成纤维细胞生长因子蛋白及mRNA表达均明显增多,分别在5～7d及7～11d达高峰,且联合治疗、对照组峰值较rhEGF、血糖控制组高(P0.05)。烫伤后7～21d,联合治疗、对照组创面愈合率高于rhEGF、血糖控制组(P0.05)。说明局部应用rhEGF在联合血糖控制下可促进糖尿病大鼠烫伤创面的愈合,可能与促进创面成纤维细胞生长因子表达有关。     

重组人促红细胞生成素对大鼠皮肤深Ⅱ°烫伤创面愈合的影响

目的研究重组人促红细胞生成素(rHuEPO)对大鼠皮肤深Ⅱ°烫伤愈合的影响。方法健康SD大鼠随机分成低剂量组(50U/mL rHuEPO)、中剂量组(100U/mL rHuEPO)、高剂量组(200U/mL rHuEPO)和生理盐水(NS)对照组,建立深Ⅱ°烫伤动物模型,并于伤后3、5、7、14、21d取创面皮肤标本,HE染色和免疫组织化学方法染色分别检测创面愈合情况及微血管密度。结果与对照组相比,rHuEPO治疗组创面愈合时间缩短,同一时相内大鼠烫伤愈合率高于对照组,微血管密度明显增加。结论rHuEPO能促进深Ⅱ°烫伤创面微血管形成,加速创面愈合。     

无定形水凝胶敷料对大鼠皮肤烫伤及创伤模型的疗效分析

目的:探讨无定形水凝胶敷料对大鼠深Ⅱ度烫伤及创伤模型的治疗应用效果。方法:分别制备大鼠深Ⅱ度烫伤及创伤模型,给予无定形水凝胶创面涂抹治疗,观察2类创面的完全脱痂时间、完全愈合时间及组织病理学特征;同时采用康惠尔水凝胶敷料(简称清创胶)作为平行对照。结果:对于深Ⅱ度烫伤和创伤创面,无定形水凝胶组和清创胶组的上皮化时间均短于相应的模型组,同一类型创面2种敷料治疗的愈合时间无明显差异,但无定形水凝胶组的完全脱痂时间短于清创胶组。病理结果显示,2种敷料使用后的皮肤烫伤创面上皮细胞、新生毛细血管及成纤维细胞数多于烫伤模型组,而炎症细胞数少于烫伤模型组;2种创面完全愈合后无定形水凝胶组的毛囊、汗腺均明显多于清创胶组。结论:无定形水凝胶主要通过促进创面上皮化缩短创面修复时间,在促进毛囊、汗腺形成上更胜一筹。     

深Ⅱ度烫伤创面早期应用重组人表皮生长因子后表皮生长因子受体的表达

背景：有研究表明重组人表皮生长因子能促进烧伤创面愈合,内源性表皮生长因子通过与表皮生长因子受体结合发挥生物学效应。 目的：观察局部应用重组人表皮生长因子对大鼠烫伤创面表皮生长因子受体的影响,分析其促进创面愈合的可能机制。 方法：制备Wistar大鼠背部深Ⅱ度烫伤模型,分为2组,对照组于创面喷洒生理盐水,实验组喷洒重组人表皮生长因子。烫伤后0,1,3,5,7,10,14,21 d取创面组织,采用Western blot检测表皮生长因子受体蛋白表达,并测定两组大鼠创面愈合率。 结果与结论：烫伤后7-21 d 实验组创面愈合率高于对照组(P < 0.05)。两组表皮生长因子受体蛋白表达在1 d明显降低(P < 0.05),随后又升高,7 d达峰值且对照组比实验组高(P < 0.05);峰值过后,对照组逐渐下降,21 d接近烫伤前水平,实验组迅速下降,14 d达谷值,随后上升,21 d接近烫伤前水平,两组差异有显著性意义(P < 0.05)。说明早期局部应用重组人表皮生长因子可影响表皮生长因子受体的表达规律,并显著促进大鼠深Ⅱ度烫伤创面愈合。     

重组人促红细胞生成素对大鼠皮肤深Ⅱ&#176;烫伤创面愈合的影响

目的研究重组人促红细胞生成素(rHuEPO)对大鼠皮肤深Ⅱ&#176;烫伤愈合的影响。方法健康SD大鼠随机分成低剂量组(50U/mL rHuEPO)、中剂量组(100U/mL rHuEPO)、高剂量组(200U/mL rHuEPO)和生理盐水(NS)对照组,建立深Ⅱ&#176;烫伤动物模型,并于伤后3、5、7、14、21d取创面皮肤标本,HE染色和免疫组织化学方法染色分别检测创面愈合情况及微血管密度。结果与对照组相比,rHuEPO治疗组创面愈合时间缩短,同一时相内大鼠烫伤愈合率高于对照组,微血管密度明显增加。结论rHuEPO能促进深Ⅱ&#176;烫伤创面微血管形成,加速创面愈合。     

壳聚糖胶原复合敷料促伤口愈合实验研究

作者用壳聚糖和冷冻动物胶原等制成新型创伤敷料,在对该敷料外用安全性进行了研究的基础上,以大鼠背部皮肤切割伤和深Ⅱ度烧伤为模型,研究该敷料对伤口是否具有促愈合作用。 实验用大鼠60只,体重250-300g。切割伤组大鼠背部去毛,乙醚麻醉后固定。于背部中线划两个直     

三维扫描技术精确控制大鼠烫伤面积动物模型的建立

目的 建立一种可精确控制烫伤面积的大鼠模型.方法 40只大鼠被随机分为5组,每组8只,根据接触94℃热水时间不同分别为6 s组、8 s组、10 s组、12 s组、14 s组,以热水接触作为致伤原因,持续时间控制烫伤深度.比较各组创面烫伤深度和愈合时间,并经病理证实.另取9只大鼠作为3D扫描组,接触94℃热水12 s,烫伤24 h后应用3D流动式双目三维扫描技术,扫描计算大鼠体表面积及烫伤部位占体表总面积的百分比,并与实体解剖测量结果进行比较.结果 12 s组烫伤创面深度可达（34.2±2.9）mm,且无毛囊及汗腺附件存在.创面愈合时间为（24.4±2.2）d,病理证实烫伤深度为深Ⅱ度～Ⅲ度;流动式双目三维扫描技术确认的烫伤面积与实体解剖测量所得结果差异无统计学意义（P〉0.05）.结论 以热水接触为致伤原因,配合三维扫描技术测量烫伤面积精确可信,该模型可以控制烫伤深度、精确烫伤面积,是研究烧（创）伤修复机制及评价创面用药的良好动物模型.     

重组人表皮生长因子凝胶与碘伏油纱治疗小面积Ⅱ度烧伤的比较

目的观察和比较重组人表皮生长因子（rhEGF）凝胶与碘伏油纱用于治疗小面积Ⅱ度烧伤的临床效果。方法95例小面积Ⅱ度烧伤患者,分成2组：其中使用rhEGF凝胶治疗的患者为rhEGF凝胶组,使用碘伏油纱治疗的患者为对照组,观察创面愈合时间、患者疼痛度、换药工作量及预后色素沉着情况并留取照片,1年后对部分患者进行随访。结果rhEGF凝胶组的治疗效果明显优于对照组。凝胶组的愈合时间【（9.82±1.52）d】明显短于对照组【（14.42±2.10）d】（P﹤0.01）,平均愈合时间提前3～5d;患者疼痛度明显减轻（VRS-5评分分别是：1.56±0.07和3.23±0.14,P﹤0.01）;换药工作量也明显缩小（治愈每1%TBSA所需要的时间分别是：（57.2±0.8）min和（84.9±4.3）min,P﹤0.01）;1年后部分患者随访证实凝胶组远期色素沉着较轻,并较少引起疤痕增生。结论rhEGF凝胶用于治疗小面积Ⅱ度烧伤效果确切,患者愈合时间缩短、疼痛度减小、换药工作量减少、预后色素沉着减轻,并且1年后随访发现多数患者效果良好。     

重组人表皮生长因子联合前列地尔作用于糖尿病溃疡创面

背景：人内源性表皮生长因子的缺乏以及血流动力学的改变会导致创面不愈合的发生。 目的：观察重组人表皮生长因子联合前列地尔作用于糖尿病溃疡动物模型创面的疗效。 方法：Wistar大鼠40只建立糖尿病溃疡动物模型,随机等分为模型组、重组人表皮生长因子组、前列地尔组和重组人表皮生长因子+前列地尔组,分别予以1%碘伏清创、重组人表皮生长因子凝胶外敷、前列地尔静脉滴注、重组人表皮生长因子凝胶外敷和前列地尔静脉滴注联合治疗。 结果与结论：干预后3,7,10,14 d观察发现,相比于模型组,重组人表皮生长因子和/或前列地尔治疗后,糖尿病皮肤溃疡大鼠溃疡面积减小、愈合时间缩短、创面动态愈合率上升(P < 0.01),且两者联合治疗的效果优于重组人表皮生长因子和前列地尔单独治疗(P < 0.01),而重组人表皮生长因子或前列地尔单独治疗的效果接近,提示重组人表皮生长因子与前列地尔联合使用比单纯使用前列地尔或单纯使用重组人表皮生长因子更能显著促进糖尿病溃疡创面的愈合。     

白芨胶载外源性重组人表皮生长因子促进伤口愈合机制

BACKGROUND: How to promote wound healing is always the research focus of the surgical physicians in the clinic. Recombinant human epidermal growth factor (rhEGF) can effectively promote wound healing. However, as a biological agent, it is easy to be decomposed under normal temperature. OBJECTIVE: To explore the mechanisms underlying the promotion of wound healing in the back of rabbits by bletilla carrying exogenous rhEGF. METHODS:Model rabbits with full-thickness skin defects in the back were treated with bletilla carrying exogenous rhEGF (combined treatment group), bletilla, rhEGF, or saline (control group). RESULTS AND CONCLUSION:The time of wound healing was the shortest (P < 0.05) and the wound healing rate was the highest (P < 0.05) in the combined treatment group. On postoperative days 3 and 10, newly formed granulation tissue, capillaries, and collagenous fibers showed by hematoxylin-eosin staining staining and Masson staining and the strongest immunoreactivity of vascular endothelial growth factor determined by immunohistochemical staining were found in the combined treatment group (P < 0.05). These findings confirm that bletilla carrying exogenous rhEGF promotes wound healing by accelerating the forming of granulation tissue, new-born capillaries, and collagenous fibers, and the effects are superior to either of them alone.     

外用重组人表皮生长因子凝胶治疗浅Ⅱ度烧伤创面的临床观察

目的观察重组人表皮生长因子在促进浅Ⅱ度烧伤创面愈合中的疗效。方法将32例四肢浅Ⅱ度烧伤患者64个烧伤部位随机分成两组,对照组32个部位应用凡士林油纱换药方法治疗,治疗组32个部位在凡士林油纱的基础上加用重组人表皮生长因子治疗,观察比较创面的愈合时间。结果治疗组较对照组创面愈合时间缩短：治疗组（8.4±1.2）d,对照组（11.6±1.8）d,两组差异有统计学意义（P〈0.01）。结论局部外用重组人表皮生长因子治疗浅Ⅱ度烧伤能加速创面愈合。     

Homologous fibronectin enhances healing of excised wounds in rats.

In order to evaluate the effects of a topical application of homologous fibronectin on the healing of skin wounds, we made 2 excisional wounds on the back skin of each rat, applied ointment with or without fibronectin purified from citrated homologous plasma, and evaluated the effect according to wound size and microscopic findings. Excised lesions treated with carrier alone, but the difference was significant only in the early phase of wound healing, 2 and 3 days, according to wound size and microscopic changes. A significant decrease in wound size could be found in both groups, treated with ointment containing and not containing fibronectin, between day 4 and 9 when wound contraction was a major contributor to wound closure. Therefore it can be concluded that topical application of fibronectin has a beneficial effect on wound healing during its early phase, but no significant influence on wound contraction.     

Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors

Recent evidence indicates that topical application of adenosine A(2A) receptor agonists, unlike growth factors, increases the rate at which wounds close in normal animals and promotes wound healing in diabetic animals as well as growth factors, yet neither the specific adenosine receptor involved nor the mechanism(s) by which adenosine receptor occupancy promotes wound healing have been fully established. To determine which adenosine receptor is involved and whether adenosine receptor-mediated stimulation of angiogenesis plays a role in promotion of wound closure we compared the effect of topical application of the adenosine receptor agonist CGS-21680 (2-p-[2-carboxyethyl]phenethyl-amino-5'-N-ethylcarboxamido-adenosine) on wound closure and angiogenesis in adenosine A(2A) receptor knockout mice and their wild-type littermates. There was no change in the rate of wound closure in the A(2A) receptor knockout mice compared to their wild-type littermates although granulation tissue formation was nonhomogeneous and there seemed to be greater inflammation at the base of the wound. Topical application of CGS-21680 increased the rate of wound closure and increased the number of microvessels in the wounds of wild-type mice but did not affect the rate of wound closure in A(2A) receptor knockout mice. Similarly, in a model of internal trauma and repair (murine air pouch model), endogenously produced adenosine released into areas of internal tissue injury stimulates angiogenesis because there was a marked reduction in blood vessels in the walls of healing air pouches of A(2A) receptor knockout mice compared to their wild-type controls. Inflammatory vascular leakage and leukocyte accumulation in the inflamed air pouch were similarly reduced in the A(2A) receptor knockout mice reflecting the reduced vascularity. Thus, targeting the adenosine A(2A) receptor is a novel approach to promoting wound healing and angiogenesis in normal individuals and those suffering from chronic wounds.     

Treatment of chronic wounds: state of the art and future concepts

The morbidity and mortality from chronic wounds of varying etiology present a significant health care problem. Multiple local disturbances and systemic disease can impair wound healing. Recently, experiments with tissue cultures and animal models have revolutionized the understanding of wound healing and the pathophysiological processes involved. In cooperation with clinicians and industrial partners novel therapeutic concepts including the topical application of growth factors and cell therapies have been developed. Cytokines that have been tested in clinical studies include epidermal growth factor, platelet-derived growth factor and fibroblast growth factor. These studies showed that an important aspect of the growth factor wound healing paradigm is the effective delivery of these polypeptides to the wound site. Current drug delivery strategies suffer from the inherent loss of drug activity due to the combined effects of physical inhibition and biological degradation. A molecular genetic approach in which genetically modified cells synthesize and deliver the desired growth factor in a time-regulated manner is a powerful means to overcome the limitations associated with the topical application of recombinant growth factor proteins.     

Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers

The effect of allogeneic cultured dermal substitute (CDS) on wound healing was evaluated in 9 intractable skin ulcers in 5 patients who had failed to improve despite conventional topical treatment with basic fibroblast growth factor (bFGF) for more than 2 months. In general, the topical application of bFGF is effective in facilitating wound healing. However, skin regeneration was very slow in the present 9 cases. In this study, to improve the condition of these wounds, allogeneic CDS was applied once a week for 2 months. The wound healing process was evaluated, focusing on the reduction ratio of wound size through the granulation tissue formation associated with epithelialization. In all 9 cases, the wound size was successfully decreased after the application of CDS, and ulcers were completely resurfaced in 2 cases. In all cases, except the 2 cases showing complete wound closure, the mean wound size decreased to 33.3% of the original size, i.e., a mean reduction ratio of 33.3%. The present results indicate that allogeneic CDS can promote wound healing of intractable skin ulcers that fail to improve despite treatment with bFGF.     

碱性成纤维细胞生长因子与小儿烧伤创面的愈合

背景：皮肤创面愈合是一个复杂的病理过程,对于创伤和创伤后感染等引起皮肤难愈合的研究一直是临床创面修复的难题,对于碱性成纤维细胞生长因子促进皮肤创面愈合的基础研究相对较多,临床应用研究较少。 目的：对碱性成纤维细胞生长因子促进皮肤创面愈合研究的文献资料趋势进行多层次分析,探讨在小儿烧伤创面愈合中的应用疗效。 方法：以电子检索方式对CNKI数据库学术期刊2002-01/2011-12收录有关碱性成纤维细胞生长因子促进皮肤创面愈合研究的文献进行分析,采用检索词为“碱性成纤维细胞生长因子;创面愈合”,运用数据库的分析功能和Excel软件图表的功能分析数据特征。 结果与结论：CNKI数据库学术期刊2002/2011收录碱性成纤维细胞生长因子促进皮肤创面愈合研究的文献共228篇,文献数量处于平稳发展趋势。《中国组织工程研究与临床康复》杂志收录的文献数量最多为26篇。解放军第304医院产出的文献最多。碱性成纤维细胞生长因子促进皮肤创面愈合研究文献的基金资助项目有16项,基金资助项目的文献共76篇,以国家重点基础研究发展计划(973)项目和国家自然科学基金资助项目的文献最多。碱性成纤维细胞生长因子在小儿烧伤创面愈合中应用的文献虽然较少,但实验结果均显示治疗效果较好,有促进小儿Ⅱ度烧伤创面愈合的作用,而且无不良反应出现。